MSU
BIIB icon

Maple Securities USA’s Biogen BIIB Stock Holding History

Maple Securities USA’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,090
Closed -$440K – 54
2015
Q2 		$440K Buy
+1,090
New +$437K 0.04% 143
2015
Q1 		– Sell
-3,000
Closed -$1.02M – 236
2014
Q4 		$1.02M Buy
+3,000
New +$971K 0.08% 67
2014
Q3 		– Sell
-1,328
Closed -$419K – 227
2014
Q2 		$419K Buy
+1,328
New +$400K 0.05% 114
2013
Q4 		– Sell
-9,049
Closed -$2.18M – 379
2013
Q3 		$2.18M Buy
9,049
+766
+9% +$171K 0.17% 113
2013
Q2 		$1.78M Buy
+8,283
New +$1.77M 0.16% 123

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Maple Securities USA's BIIB Position: Q3 2015 in Review

Maple Securities USA sold out of Biogen (BIIB) in Q3 2015, closing a stake of 1,090 shares — an estimated $440K sold.

Maple Securities USA first reported a position in BIIB in Q2 2013 and held it in 5 quarters. The position peaked at $2.18M in Q3 2013. 923 funds tracked by Wall St. Rank hold BIIB as of Q3 2015.

  • Maple Securities USA reported no remaining Biogen position as of Q3 2015 after selling out during the quarter.
  • Maple Securities USA sold 1,090 Biogen shares in Q3 2015, an estimated $440K.
  • Maple Securities USA first reported a position in Biogen in Q2 2013 and held it in 5 quarters.
  • Maple Securities USA's Biogen position peaked at $2.18M in Q3 2013.
  • 923 funds tracked by Wall St. Rank held Biogen as of Q3 2015.

Based on Maple Securities USA's 13F filing for Q3 2015, filed 3 Nov 2015.